Dahuang Zhechong Pill Alleviates Liver Fibrosis Progression by Regulating p38 MAPK/NF-κ B/TGF-β1 Pathway
Chinese Journal of Integrative Medicine · 2024
DOI: 10.1007/s11655-024-3801-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Chinese Journal of Integrative Medicine, 2024. Verfasst von Xiao-Yan He und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Chengdu University of Traditional Chinese Medicine, Chengdu, 610036, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Drugs, Chinese Herbal, p38 Mitogen-Activated Protein Kinases, NF-kappa B. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To explore the effect and mechanism of Dahuang Zhechong Pill (DHZCP) on liver fibrosis. METHODS: Liver fibrosis cell model was induced by transforming growth factor-β (TGF-β) in hepatic stellate cells (HSC-T6). DHZCP medicated serum (DMS) was prepared in rats. HSC-T6 cells were divided into the control (15% normal blank serum culture), TGF-β (15% normal blank serum + 5 ng/mL TGF-β), DHZCP (15% DMS + 5 ng/mL TGF-β), DHZCP+PDTC [15% DMS + 4 mmol/L ammonium pyrrolidine dithiocarbamate (PDTC)+ 5 ng/mL TGF-β], and PDTC groups (4 mmol/L PDTC + 5 ng/mL TGF-β). Cell activity was detected by cell counting kit 8 and levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the cell supernatant were determined by enzyme-linked immunosorbnent assay. Western blot was used to measure the expressions of p38 mitogen-activated protein kinase/nuclear factor kappa B/transforming growth factor-β1 (p38 MAPK/NF-κ B/TGF-β1) pathway related proteins, and the localization and expressions of these proteins were observed by immunofluorescence staining. RESULTS: DHZCP improves the viability of cells damaged by TGF-β and reduces inflammatory cytokines and ALT and AST levels in the supernatant of HSC-T6 cells induced with TGF-β (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Chengdu University of Traditional Chinese Medicine, Chengdu, 610036, China.
- Department of Neurology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 610072, China.
- School of Public Health, Chengdu University of Traditional Chinese Medicine, Chengdu, 610036, China. wulijuan@cdutcm.edu.cn.
Zitieren
APA
He, X. Y., Xiong, X. J., Liu, M. J., Liang, J. T., Liu, F. Y., Xiao, J. Y., & Wu, L. J. (2024). Dahuang Zhechong Pill Alleviates Liver Fibrosis Progression by Regulating p38 MAPK/NF-κ B/TGF-β1 Pathway. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-024-3801-x
Vancouver
He XY, Xiong XJ, Liu MJ, Liang JT, Liu FY, Xiao JY, et al. Dahuang Zhechong Pill Alleviates Liver Fibrosis Progression by Regulating p38 MAPK/NF-κ B/TGF-β1 Pathway. Chinese Journal of Integrative Medicine. 2024. doi:10.1007/s11655-024-3801-x
BibTeX
@article{He2024,
author = {He, Xiao-Yan and Xiong, Xiao-Jiao and Liu, Mei-Jun and Liang, Jing-Tao and Liu, Fu-You and Xiao, Jing-Yi and Wu, Li-Juan},
title = {Dahuang Zhechong Pill Alleviates Liver Fibrosis Progression by Regulating p38 MAPK/NF-κ B/TGF-β1 Pathway},
journal = {Chinese Journal of Integrative Medicine},
year = {2024},
doi = {10.1007/s11655-024-3801-x}
}
EUVIMED